| Literature DB >> 18793448 |
Manuel W Hetzel1, Brigit Obrist, Christian Lengeler, June J Msechu, Rose Nathan, Angel Dillip, Ahmed M Makemba, Christopher Mshana, Alexander Schulze, Hassan Mshinda.
Abstract
BACKGROUND: Malaria is still a leading child killer in sub-Saharan Africa. Yet, access to prompt and effective malaria treatment, a mainstay of any malaria control strategy, is sub-optimal in many settings. Little is known about obstacles to treatment and community-effectiveness of case-management strategies. This research quantified treatment seeking behaviour and access to treatment in a highly endemic rural Tanzanian community. The aim was to provide a better understanding of obstacles to treatment access in order to develop practical and cost-effective interventions.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18793448 PMCID: PMC2564938 DOI: 10.1186/1471-2458-8-317
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Sample characteristics
| under 5 years | 80 | 58.4 | 29 | 50.9 |
| over 12 years | 57 | 41.6 | 28 | 49.1 |
| Female | 76 | 55.5 | 25 | 43.9 |
| Male | 61 | 44.5 | 32 | 56.1 |
| Ulanga DSS villages | 53 | 38.7 | 31 | 54.4 |
| Kilombero DSS villages | 44 | 32.1 | 26 | 45.6 |
| Ifakara | 40 | 29.2 | NA | NA |
| Muslim | 51 | 37.2 | 21 | 36.8 |
| Christian | 84 | 61.3 | 36 | 63.2 |
| Mean (years) | 5.4 (95% CI 4.83, 5.89) | 6.5 (95% CI 6.01, 6.97) | ||
| Median (years) | 7 (51.1% of sample) | 7 (77.2% of sample) | ||
| Yes | 68 | 49.6 | 33 | 57.9 |
| Possibly | 18 | 13.1 | 3 | 5.3 |
| Uncertain | 13 | 9.5 | 7 | 12.3 |
| No | 38 | 27.7 | 14 | 24.6 |
Figure 1Immediate help seeking actions taken on the day of illness onset or the day after. Error bars represent 95% confidence intervals.
Key indicators for help seeking and access to malaria treatment in individuals with fever in the preceding two weeks
| Episodes treated | 80 | 100 (95.5–100) | 57 | 100 (93.7–100) | ||
| Modern medicine | 80 | 100 (95.5–100) | 56 | 98.3 (90.6–100) | 0.416∞ | |
| Antimalarial drug (AM) | 71 | 88.8 (79.7–94.7) | 58.2 (88.6) | 47 | 82.5 (70.1–91.3) | 0.293§ |
| - SP | 38 | 47.5 (36.2–59.0) | 23.7 (33.8) | 25 | 43.9 (30.7–57.6) | 0.673§ |
| - SP correctly dosed | 13 | 16.25 (8.9–26.2) | 18 | 31.6 (19.9–45.2) | ||
| - amodiaquine | 10 | 12.5 (6.2–21.8) | 22.1 (29.3) | 5 | 8.8 (2.9–19.3) | 0.491§ |
| - amodiaquine correctly dosed | 5 | 6.3 (2.1–14.0) | 3 | 5.3 (1.1–14.6) | 1.000∞ | |
| - quinine | 43 | 53.8 (42.2–65.0) | 11.9 (23.5) | 23 | 40.4 (27.6–54.2) | 0.122§ |
| - other AM | 2 | 2.5 (0.3–8.7) | 1 | 1.8 (0.0–9.4) | 1.000∞ | |
| Antipyretic only | 9 | 11.3 (5.3–20.3) | 9 | 15.8 (7.5–27.9) | 0.438§ | |
| Antibiotic | 8 | 10.0 (4.4–18.8) | 2 | 3.5 (0.4–12.1) | 0.194∞ | |
| Health facility visit | 61 | 76.3 (65.4–85.1) | 32 | 56.1 (42.4–69.3) | ||
| AM from health facility | 43 | 53.8 (42.2–65.0) | 17 | 29.8 (18.4–43.4) | ||
| AM not from health facility | 28 | 35.0 (24.7–46.5) | 30 | 52.6 (39.0–66.0) | ||
| AM from drug store | 19 | 23.8 (15.0–34.6) | 26 | 45.6 (32.4–59.3) | ||
| AM from general shop | 8 | 10.0 (4.4–18.8) | 4 | 7.0 (2.0–17.0) | 0.761∞ | |
| AM from home stock (or relative/neighbour) | 10 | 12.5 (6.2–21.8) | 6 | 10.5 (4.0–21.5) | 0.723§ | |
| Exclusive home-management with AM3 | 14 | 17.5 (9.9–27.6) | 18 | 31.6 (19.9–45.2) | 0.055§ | |
1One episode may be treated with several drugs from various sources; 2Tanzania Demographic and Health Survey 2004–05 (data for Morogoro Region in brackets); 3Episodes never brought to a health facility; * comparison of children and adults; ∞Fisher's exact test; §Chi-square test
Figure 2Estimated effective coverage of fever treatment modelled based on patients' or caretakers' accounts. Percentages are proportions of the study sample with a reported recent fever. ① Episode treated. ② Drug administered. ③ Antimalarial administered. ④ Recommended antimalarial. ⑤ Recommended antimalarial on same or next day. ⑥ Recommended antimalarial on same/next day, in correct dose. ⑦ Recommended antimalarial on same/next day, correct dosage, appropriate considering reported symptoms.
Median reported expenditure per one dose of antimalarial treatment in health facilities and drug stores (in TShs). US $1 = TShs. 1,117 (July 2004)*
| Health facility | 35 | 540 (0–1100) | 0 to 3000 | 15 | 500 (200–700) | 0 to 2700 |
| Drug store | 16 | 600 (400–900) | 0 to 3600 | 21 | 540 (400–800) | 60 to 2000 |
* OANDA currency converter
IQR = Interquartile range
Figure 3Graphical illustration of treatment indicators assessed in the multivariate models. Circles are roughly proportional to the percentage of patients. rAM = recommended antimalarial (SP, amodiaquine, quinine). * includes only SP and amodiaquine.
Univariate and multivariate analyses of predictors for administration of a recommended antimalarial (SP, amodiaquine or quinine)
| Adult (> 12 years) | 1 | |||||
| Child (< 5 years) | 1.67 | 0.66–4.26 | 0.280 | |||
| 0.85 | 0.73–0.99 | 0.041 | ||||
| Home | 1 | 1 | ||||
| Shamba | 0.19 | 0.07–0.51 | 0.001 | 0.29 | 0.08–1.14 | 0.076 |
| No | 1 | 1 | ||||
| Yes | 5.05 | 1.73–14.74 | 0.003 | 3.24 | 0.85–12.34 | 0.084 |
| No | ||||||
| Yes | 2.48 | 0.78–7.88 | 0.125 | 3.60 | 0.73–17.86 | 0.117 |
| Malaria/degedege | 1 | 1 | ||||
| Homa | 0.10 | 0.04–0.29 | 0.000 | |||
| No | 1 | |||||
| Yes | 0.61 | 0.17–2.23 | 0.451 | |||
| No | 1 | 1 | ||||
| Yes | 0.24 | 0.07–0.81 | 0.022 | |||
| No | 1 | 1 | ||||
| Yes | 4.46 | 1.69–11.78 | 0.003 | |||
| No | 1 | |||||
| Yes | 2.10 | 0.67–6.59 | 0.201 | |||
| 0.01 | 0.00–0.43 | 0.017 | ||||
| Ifakara | 1 | |||||
| DSS | 0.22 | 0.05–0.98 | 0.046 | |||
* 137 observations; ** 136 observations; *** 76 observations (DSS only); 1 Incl. health facilities, drug stores and general shops stocking antimalarials in mid-2004